FAQ on Quantum BioPharma Ltd.'s Appointment of Kevin Malone as Board Advisor and Company Overview
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) has appointed Kevin Malone, a seasoned financial advisor and anti-corruption advocate, as a board advisor, aligning with its shareholder protection values and therapeutic focus on neurodegenerative and metabolic disorders.
Who is Kevin Malone and why was he appointed to Quantum BioPharma’s Board of Directors?
Kevin Malone is a seasoned financial advisor with over 40 years of family experience in wealth management, known for his work in market pattern recognition and his outspoken stance against trading manipulation. His appointment aligns with Quantum BioPharma’s shareholder protection values and its focus on developing treatments for neurodegenerative and metabolic disorders.
What is Quantum BioPharma Ltd. focused on?
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development.
What is Lucid-MS and who is developing it?
Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It is being developed by Lucid Psycheceuticals Inc., a wholly owned subsidiary of Quantum BioPharma.
What is UNBUZZD and how is Quantum BioPharma involved with it?
UNBUZZD is a product invented by Quantum BioPharma, which has spun out its OTC version to Celly Nutrition Corp. Quantum BioPharma retains ownership of 25.71% of Celly Nutrition and receives royalty payments from sales of UNBUZZD.
Where can I find more information about Quantum BioPharma Ltd.?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
What are the terms of the agreement between Quantum BioPharma and Celly Nutrition Corp.?
The agreement includes royalty payments of 7% of sales from UNBUZZD until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
What is BioMedWire and how is it related to Quantum BioPharma?
BioMedWire is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It provides news and updates on companies like Quantum BioPharma, including the announcement of Kevin Malone’s appointment as a board advisor.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 119619